language
2026-01-02
Developers are recombining or sharpening established drugs, molecules and mechanisms to create a new generation of neurology therapies.
Neurology is back. A suite of high profile approvals — from Biogen and Eli Lilly’s Alzheimer’s disease drugs to Bristol Myers Squibb’s schizophrenia treatment Cobenfy (xanomeline and trospium chloride) and, most recently, Vertex Pharmaceuticals’ non-opioid pain treatment Journavx (suzetrigine) — has placed the category firmly back onto dealmakers’ radars.
本文摘选自《浦江科技评论》2025年4月刊封面专题 “中国创新药十年之路”，作者：上海科创金融研究院研究团队。
16
2025/04
近日，专注于疼痛治疗的创新药物研发新锐企业——阳光安津（南京）生物医药科技有限公司（下称“阳光安津”）正式宣布完成超亿元Pre-A轮融资。本轮融资由启明创投领投。融资资金将用于全球领先的疼痛治疗研发管线临床前和早期临床阶段的开发，加速靶向钠离子通道Nav1.8小分子药物的研发进度，增强其在全球生物医药领域的竞争力。
15
2025/01
Iongen Therapeutics Secures Over 100 Million RMB in Pre-A Financing Led by Qiming Venture Partners
NANJING, Jan. XX, 2025 -- Iongen Therapeutics Co., Ltd. ("Iongen Therapeutics"), a biotechnology company developing best-in-class non-opioid pain medicines, announced the successful completion of its Pre-A financing round, raising over 100 million RMB.
10
2025/01
7月19日下午，阳光安津（南京）生物医药科技有限公司在江北新区南京生物医药谷落成启航，江北新区生命健康产业发展党工委委员、管办副主任李金兵，阳光安津共同创始人雷晓光博士和杨勇博士等出席开业典礼。
20
2022/07
Want more product service? Leave us a message
We will contact you within one working day. Please pay attention to your email.